Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...
In their places are projected to be Novo Nordisk's (NVO) type 2 diabetes med Ozempic (semaglutide) and Regeneron Pharmaceuticals (NASDAQ:REGN)/Sanofi's (SNY) Dupixent (dupilumab), used for ...
Some results have been hidden because they may be inaccessible to you